CMS coverage guidance draws medtech, drug industry concerns

01/31/2013 | Bloomberg BNA (free content)

Draft guidance released by CMS in November on the use of coverage with evidence development (CED) for determining Medicare coverage elicited industry concerns. The guidance suggests available data used to obtain FDA OKs "will rarely be sufficient for Medicare coverage," creating more confusion on the use of CED, said Chandra Branham of the Advanced Medical Technology Association.

View Full Article in:

Bloomberg BNA (free content)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ